AGC Biologics Archives | Page 3 of 3

Home / Posts tagged AGC Biologics (Page 3)

AGC Biologics Enters Agreement to Acquire Facility in Longmont, CO, Eyeing to Significantly Expand Their Cell and Gene Therapy Capabilities and Offerings

Seattle, July 1 (Korea Bizwire) — AGC Biologics, a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced the signing of a purchase agreement for a state-of-the-art Cell and Gene Therapy commercial manufacturing facility in Longmont, Colorado, currently owned by Novartis Gene Therapies. Once the transaction closes, pending final due diligence, the facility will [...]

Chemomab Therapeutics and AGC Biologics Expand Partnership to Manufacture CM-101 for Phase II/III

TEL AVIV, Israel and SEATTLE, Wash., June 23 (Korea Bizwire) — Chemomab Therapeutics, Ltd. (NASDAQ: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, and AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced an expanded partnership to [...]

AGC Biologics’ Heidelberg Facility to Further Supply Plasmid DNA for COVID-19 Vaccine

Seattle, June 7 (Korea Bizwire) — AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced its partnership with BioNTech SE (Nasdaq BNTX) to further supply Plasmid DNA (pDNA) starting material for the Pfizer-BioNTech COVID-19 vaccine, at AGC’s Heidelberg, Germany facility. “We are honored that BioNTech has entrusted us to become [...]

AGC Inc. Receives Best Acquisition Award for Adding the Former MolMed into AGC Biologics

Seattle, May 19 (Korea Bizwire) — AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced their win of the M&A Award for Best Acquisition, Cross-Border into Italy, presented by KPMG, Fineurop Soditic, and others. This award is dedicated to showcasing the best of the Italian M&A market. “We are incredibly honored [...]

Oculis Selects AGC Biologics’ Heidelberg Facility to Manufacture OCS-02

Seattle, May 6 (Korea Bizwire) — AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced its partnership with Oculis to manufacture OCS-02, a Phase II investigational drug targeting both Dry Eye Disease and Anterior Uveitis, at its Heidelberg facility. “We are very pleased that Oculis has chosen us to manufacture [...]

Horizon Therapeutics plc Selects AGC Biologics to Further Supply KRYSTEXXA® (pegloticase injection) at AGC’s Copenhagen Facility

Seattle, April 30 (Korea Bizwire) — AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced the expansion of their partnership with Horizon Therapeutics plc (Nasdaq: HZNP), to include the manufacturing of KRYSTEXXA® (pegloticase injection) – a biologic medicine for treatment of chronic gout refractory to conventional therapies (uncontrolled gout), at its [...]

AGC Biologics Expands Partnership with Rocket Pharmaceuticals

Seattle, April 20 (Korea Bizwire) — AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced it has expanded its partnership with Rocket Pharmaceuticals, a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders. Through the expanded partnership, AGC Biologics will bolster the security of [...]

AGC Biologics Appoints Jun Takami to General Manager/Site Head of Their Chiba, Japan Site

Chiba, April 8 (Korea Bizwire) — AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced the appointment of Jun Takami as the General Manager/Site Head, to lead the continued successful operations as well as continuous improvements at its Chiba, Japan site. Mr. Takami’s transition to the Site Head comes [...]

AGC Biologics to Present Their End-to-End Cell and Gene Therapy Offering at ARM’s Meeting on the Mediterranean Conference

SEATTLE, April 5 (Korea Bizwire) — AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced it will be attending Alliance for Regenerative Medicine’s virtual Meeting on the Mediterranean conference this week, from April 6 – 9, 2021 as a first-time attendee and Gold- and Agenda-level sponsor. “We’re incredibly honored to be attending [...]